Anti-SV2C single domain nanobodies for molecular imaging in androgen receptor positive prostate cancer
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · HER2/EGFR in Cancer Research · Radiopharmaceutical Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. TRAF7-targeted HOXA5 acts as a tumor suppressor in prostate cancer progression and stemness via transcriptionally activating SPRY2 and regulating MEK/ERK signaling10.1038/s41420-023-01675-9 ↗
2. Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer10.1001/jamaoncol.2017.3588 ↗
3. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?10.1016/j.euf.2019.05.005 ↗
4. Androgens and androgen receptor signaling in prostate tumorigenesis10.1530/JME-14-0203 ↗
5. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics10.1002/pros.20191 ↗
6. Eighty Years of targeting androgen receptor activity in prostate cancer: the fight goes on10.3390/cancers13030509 ↗
7. Structural insights into the interaction of botulinum neurotoxin a with its neuronal receptor SV2C10.1016/j.toxicon.2019.11.010 ↗
8. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A10.1038/nsmb.3245 ↗
9. SV2 is the protein receptor for botulinum neurotoxin A10.1126/science.1123654 ↗
10. Synaptic vesicle protein 2, a new neuroendocrine cell marker10.1016/S0002-9440(10)64645-7 ↗
11. Validation of SV2A-targeted PET imaging for noninvasive assessment of neuroendocrine differentiation in prostate cancer10.3390/ijms222313085 ↗
12. Synaptic vesicle 2C and its synaptic-related function10.1016/j.cca.2017.07.029 ↗
13. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment10.1242/jcs.02658 ↗
14. 〈https://www.proteinatlas.org/ENSG00000122012-SV2C/cell+line〉.
15. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo10.1002/pros.20958 ↗
16. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs10.1186/1471-2490-6-12 ↗
17. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study10.1016/S0090-4295(03)00477-1 ↗
18. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates10.1016/j.urology.2004.10.077 ↗
19. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia10.1111/j.1464-410X.2006.06479.x ↗
20. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates10.1016/j.urology.2005.04.029 ↗
21. Increased expression of AKT3 in neuroendocrine differentiated prostate cancer cells alters the response towards anti-androgen treatment10.3390/cancers13030578 ↗
22. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines
23. Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery10.3390/antib8010012 ↗
24. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses10.1093/nar/gkx247 ↗
25. Biodistribution of [68Ga]PSMA-HBED-CC in patients with pros tate cancer: characterization of uptake in nor mal organs and tumour lesions10.1007/s11307-016-0945-x ↗
26. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer10.2967/jnumed.112.111021 ↗
27. Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET10.2967/jnumed.115.171306 ↗
28. Pharmacokinetics of single domain antibodies and conjugated nanoparticles using a hybrid near infrared method10.3390/ijms22168695 ↗
29. A role for SV2C in basal ganglia functions10.1016/j.brainres.2013.02.041 ↗
30. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family10.1016/S0306-4522(99)00370-X ↗
31. Differential expression of synaptic vesicle protein 2 (SV2) isoforms10.1523/JNEUROSCI.14-09-05223.1994 ↗
32. Novel PET imaging methods for prostate cancer10.1007/s00345-020-03344-3 ↗
33. Mitochondrial localization, import, and mitochondrial function of the androgen receptor10.1074/jbc.RA118.006727 ↗
34. SV2A controls the surface nanoclustering and endocytic recruitment of Syt1 during synaptic vesicle recycling10.1111/jnc.16186 ↗
35. Synaptic vesicle glycoprotein 2C: a role in Parkinson's disease10.3389/fncel.2024.1437144 ↗
36. PET imaging of FSHR expression in tumors with 68Ga-Labeled FSH1 Peptide10.1155/2017/2674502 ↗
37. Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET10.1186/s13550-023-01043-9 ↗
38. Development and validation of a kit formulation of [68Ga]Ga-P15-041 as a bone imaging agent10.1016/j.apradiso.2020.109485 ↗
39. The design and preclinical evaluation of a single-label bimodal nanobody tracer for image-guided surgery10.3390/biom11030360 ↗
40. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours10.1016/j.jconrel.2019.11.014 ↗
41. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance10.1021/acschemneuro.9b00351 ↗
42. Machine learning models for diagnosis and prognosis of Parkinson's disease using brain imaging: general overview, main challenges, and future directions10.3389/fnagi.2023.1216163 ↗
43. A general protocol for the generation of nanobodies for structural biology10.1038/nprot.2014.039 ↗
44. Selection of human antibody fragments by phage display10.1038/nprot.2007.448 ↗
45. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies10.1016/S0167-4838(99)00030-8 ↗
46. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues10.1038/s43018-022-00344-7 ↗